Efficacy and safety of emodepside 2.1%/praziquantel 8.6% spot-on formulation in the treatment of feline aelurostrongylosis.

Author(s): Traversa D, Milillo P, Di Cesare A, Lohr B, Iorio R, Pampurini F, Schaper R, Bartolini R, Heine J

Affiliation(s): Department of Comparative Biomedical Sciences, Faculty of Veterinary Medicine, Teramo, Italy. dtraversa@unite.it

Publication date & source: 2009-08, Parasitol Res., 105 Suppl 1:S83-9.

Publication type: Comparative Study; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

The objective of the present study was to evaluate the efficacy and safety of the antiparasitic spot-on formulation containing emodepside 2.1%/praziquantel 8.6% (Profender, Bayer) in the treatment of natural feline infection with the lungworm Aelurostrongylus abstrusus (Nematoda, Strongylida). Efficacy of Profender given once at the licensed dose was tested in comparison to a control oral formulation containing fenbendazole 18.75% (Panacur, Intervet) given over three consecutive days at the licensed dose. Efficacy assessment was based on larvae per gramme of faeces (LPG) counts, measured on days 28 +/- 2 following treatment and compared to counts on days -6 to -2. In total 24 cats treated either with Profender (n = 12) or with Panacur (n = 12) were included in the assessment of efficacy and safety. Mean LPG post-baseline counts (days 28 +/- 2) were 1.3 LPG for both Profender and Panacur, demonstrating similar efficacy of 99.38% for Profender and 99.29% for the control product. No treated animals showed adverse events. This trial demonstrated that both Profender spot-on formulation and oral paste Panacur are safe and effective in the treatment of aelurotrongylosis in cats. Future practical perspectives in feline medicine and the major advantages of the spot-on product compared to the oral paste are discussed.